Abstract
The etiology of inflammation, edema, and smoothmuscle contraction characteristic of inflammatory boweldisease is not clearly understood. There is evidencethat several neuropeptides, including substance P (SP), may play a role. In this study weevaluated the ability of a SP-antagonist (SR140333) tomodify the course of experimental colitis induced in therat by trinitrobenzene sulfonic acid (TNB). Colitis was induced in 24 rats using TNB applied byintrarectal enema. Twelve TNB-treated rats receivedSR140333, 0.1 mg/kg intraperitoneally, 30 min before theadministration of TNB and every 48 hr until death. Twelve rats receiving only intrarectal 0.9%saline served as controls. Rats of each group werekilled after 14 days. At day 14, the control groupshowed no signs of inflammation whereas the TNB-treated rats without SR140333 treatment exhibited awell-established colitis. The TNB-treated group had ahigher level of inflammation, as seen histologically andby the significantly greater weight of colon strips, compared to the controls (0.30 ± 0.09 gvs 0.13 ± 0.03 g, P < 0.001) and to theSR140333-treated rats (0.30 ± 0.09 g vs 0.14± 0.05 g, P < 0.001). In addition, smoothmuscle contractility was significantly reduced in the inflamedcolons of TNB-treated rats when compared with thecontrols (carbachol: 42.7 ± 20.3 vs 254.2± 69.78 mg/mm2± 10.02 vs 89.45± 23.17 mg/mm2 11.4 ± 2.2 vs 98.32 ± 33.57mg/mm21). However, SR140333-treated ratsshowed a recovery from inflammation and motoralterations caused by TNB (carbachol: 150.9 ±46.1 mg/mm21; SP: 32.5 ± 9.4 mg/mm25; KCl:125.7 ± 36.1 mg/mm21). In conclusion,treatment with SP antagonist SR140333 reduces theseverity of colitis and has beneficial effects on theconcomitant alterations of contractility. Thus, theblockade of substance P may represent a possibility inthe treatment of intestinal inflammation.
Similar content being viewed by others
REFERENCES
Chaudary NA, Travelor SC: Human colonic motility: a comparative study of normal subjects, patients with ulcerative colitis and patients with irritable bowel syndrome. I. Resting patterns of motility. Gastroente rology 40:1–17, 1961
Grossi L, McHugh K, Collins SM: On the specificity of altered muscle function in experimental colitis in rats. Gastroenterology 104:1049–1056, 1993
Vermillion D, Collins SM: Increased responsiveness of jejunal longitudinal muscle in Trichinella-infected rats. Am J Physiol 254:G124–G129, 1988
Weihe E, Kre kel J: The neuroimmune connection in human tonsils. Brain Behav Immun 5:41–54, 1991
Hagermark O, Hokfelt T, Pernow B: Flare and itch induced by substance P in human skin. J Invest Dermatol 71:233–235, 1978
Lembeck F, Holzer P: Substance P as neurogenic mediator of antidromic vasodilatation and neurogenic plasma extravasation. Naunyn-Schmie deberg's Arch Pharmacol 310:175–183, 1979
Lembeck F: Substance P and sensory neurons. In Substance P. Metabolism and Biological Actions. CC Jordan, P Oehme (eds). London, Taylor and Francis, 1985, pp 137–151
Levine JD, Moskowitz MA, Basbaum AI: The contribution of neurogenic inflammation in experimental arthritis. J Immunol 135:843s-846s, 1985
Mandahl A, Bill A: Ocular response s to antidromic trigeminal stimulation, intracameral prostaglandin E1 and E2, capsaicin and substance P. Acta Physiol Scand 112:331–338, 1981
Büchler M, Weihe E, Friess H, Malfertheiner P, Bockman DE, Müller S, Nohr D, Beger HG: Changes in peptidergic innervation in chronic pancreatitis. Pancreas 7:183–192, 1992
Fink T, Di Sebastiano P, Büchler MW, Beger HG, Weihe E: Growth-associated protein-43 and protein gene-product 9.5 innervation in human pancreas: Changes in chronic pancreatitis. Neuroscience 63(1):249–266, 1994
Di Sebastiano P, Fink T, Weihe E, Frie ss H, Beger HG, Büchler M: Changes of protein gene product 9.5 in the inflamed appendix. Dig Dis Sci 40(2):366–372, 1995
Di Sebastiano P, Fink T, Weihe E, Frie ss H, Innocenti P, Beger HG, Büchler MW: Immune cells infiltration and growth associated protein-43 correlate with pain in chronic pancreatitis. Gastroenterology 112:1648–1655, 1997
Bjorck S, Dahlstrom A, Johansson L, Ahlman H: Treatment of the mucosa with local anesthetics in ulcerative colitis. Agents Actions 35(suppl):C60–C72, 1992
Pernov B: Substance P: Present status and future prospects. In Substance P. Metabolism and Biological Actions. CC Jordan, P Oehme (eds). London, Taylor and Francis, 1985, pp 187–196
Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL: Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96:795–803, 1989
Emonds-Alt X, Doutremepuich JD, Heaulme M, Neliat G, Santucci V, Steinberg R, Vilain P, Bichon D, Ducoux JP, Proietto V, Van Broek D, Soubrié P, Le Fur G, Brelière JC: In vitro and in vivo biological activities of SR 140333, a novel potent non-peptide tachykinin NK1 receptor antagonist. Eur J Pharmacol 250:403–413, 1993
Barrett KE: Neurogenic inflammation in the intestine. Gastroenterology 108:295–296, 1995
McCafferty DM, Sharkey KA, Wallace JL: Beneficial effects of local or systemic lidocaine in experimental colitis. Am J Physiol 266:G560–G567, 1994
Pothoulakis C, Castagliuolo I, LaMont TJ, Jaffer A, O'Keane JC, Snider RM, Leeman SE: CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin but not cholera toxin. Proc Natl Acad Sci USA 91:947–951, 1994
Wallace JL, MacNaughton WK, Morris GP, Beck PL: Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 96:29–36, 1989
Higa A, McKnight GW, Wallace JL: Attenuation of epithelial injury in acute experimental colitis by immunomodulators. Eur J Pharmacol 239:171–176, 1993
Elson CO, Balfour Sartor R, Tennyson GS, Riddel RH: Experimental models of inflammatory bowel disease. Gastroenterology 109:1344–1367, 1995
Fax-Robichaud AE, Collins SM: Altered calcium-handling properties of jejunal smooth muscle from nematode-infected rats. Gastroenterology 91:1462–1469, 1986
Cohen JD, Kao HW, Tau ST, Lechago J, Snape WS: Effects of acute experimental colitis on rabbit colonic smooth muscle. Am J Physiol 251:G538–G545, 1986
Renzi D, Calabro A, Panerai C, Tramontana M, Evangelista S, Milani S, Surrenti C: De creased substance P and neurokinin A tissue levels are associated with enhanced beta-preprotachikinin gene expression in experimental TNB-colitis. Gastroenterology 108:A902, 1995
Rights and permissions
About this article
Cite this article
Di Sebastiano, P., Grossi, L., Di Mola, F.F. et al. SR140333, a Substance P Receptor Antagonist, Influences Morphological and Motor Changes in Rat Experimental Colitis. Dig Dis Sci 44, 439–444 (1999). https://doi.org/10.1023/A:1026639509036
Issue Date:
DOI: https://doi.org/10.1023/A:1026639509036